World Growth Factors (Blood And Tissue) Market

World Growth Factors (Blood And Tissue) Market

This report analyzes the worldwide markets for Growth Factors (Blood And Tissue) in Millions of US$. The major product segments analyzed are Blood Growth Factors (Erythropoietins, Colony Stimulating Factors, Interferons, & Interleukins), and Tissue Growth Factors. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2015. The report profiles 90 companies including many key and niche players worldwide such as Amgen, Inc., BioMimetic Therapeutics, Inc., Biopharm GmbH, Bolder Biotechnology, Inc., Alseres Pharmaceuticals, Inc., Ceregene Inc., FibroGen Inc., FzioMed Inc., FzioMed Inc., GeneMedix PLC, Insmed Inc., Johnson & Johnson, Janssen-Ortho, Inc., Lonza Group, Maxygen, Inc., Merck Serono International S.A., NsGene A/S, PeproTech, Inc., Rentschler Biotechnologie GmbH, F. Hoffmann-La Roche Ltd., Chugai Pharmaceutical Co. Ltd., Genentech, Inc., Shantha Biotechnics, Scil Proteins GmbH, and Wockhardt Ltd. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.

GROWTH FACTORS (BLOOD AND TISSUE) MCP-1217
A GLOBAL STRATEGIC BUSINESS REPORT


CONTENTS


I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability And Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions And Scope Of Study I-3
Blood Growth Factors I-3
Erythropoietins I-4
Colony Stimulating Factors I-4
Interferons I-4
Interleukins I-4
Tissue Growth Factors I-4


II. EXECUTIVE SUMMARY

1. Introduction II-1
Growth Factors: A Preface II-1
Growth Factors: Their Role and Related Applications II-1
Growth Factors: Adding a New Dimension II-1
Growth Factors: Classification Based on Activity II-1
Recent Trends & Developments II-2
Recombinant Human Erythropoietin: Gradually Gaining Dominance II-2

2. Market Overview II-3
Analysis by Region II-3
US: The Single Largest Market II-3
Growth Factors Market in Europe II-3
Market for Growth Factors in Rest of World II-3
Table 1: World Market for Growth Factors (2000-2010):
Geographic Regions Ranked by CAGR -US, Europe, Japan, and
Rest of World (includes corresponding Graph/Chart) II-3
Analysis by Growth Factor Type II-4
EPO - The Lead ‘Factor’ II-4
Leading EPO Drugs Worldwide II-4
Market Comparison of Erythropoietin-Based Drugs in America
and European Union: Classification Based on Key Parameters II-5
Patent Expiries of Major Biopharmaceutical Drugs II-5

3. Market Dynamics II-6
Dethroning the Leaders II-6
Expiration of Patents Fuels Competition and Sales II-6
India - At the Center Stage II-6
Side Effects - Still a Concern II-6
CDER- A Regulatory Review Authority for Growth Factors II-7

4. Outlook II-8
Innovative Delivery System Shows Potential for Accelerating
Use of Growth Factors II-8
Cytokines- Vital Growth Propellers for the Future of New Drugs II-8
Brain Derived Neurotrophic Factor (BDNF) Finds Increased
Application II-8
Age-Related Diseases - Their Influence on Effective Therapies II-8
Copaxone Finds Novel Applications II-9
Mimetic Growth Factors - Exhibiting Promising Potential II-9

5. Industry Issues II-10
Development of Cost Effective Methods - Need of the Hour II-10
Influence of Neurotrophic Factors on Brain Cell Development II-10
Combination of Interferons and Ribavirin Develops More Anemia
Cases II-10

6. Competitive Trends II-11
RegeneRx Focuses on Wound Healing Market II-11
DRL Introduces a Program to Propel its Biogenerics Business II-11

7. Growth Factors - An Overview II-12
Blood Growth Factors II-12
Erythropoietins II-12
Types of Erythropoietins II-12
Epoetin II-12
Darbepoetin II-13
Aranesp® II-13
Aranesp Vs Other EPOs II-13
Recombinant Human EPO (rHuEPO) II-13
Table 2: World Market for Erythropoietins (2000-2010):
Geographic Regions Ranked by CAGR - Europe, US, Japan and
Rest of World (includes corresponding Graph/Chart) II-14
Colony Stimulating Factors II-14
Granulocyte-Colony Stimulating Factor II-14
Granulocyte Macrophage-Colony Stimulating Factor II-14
Other Colony Stimulating Factors II-14
Macrophage Colony Stimulating Factor (M-CSF) II-15
Key Functions of M-CSF II-15
Side-Effects of Colony-Stimulating Factors II-15
Table 3: World Market for Colony Stimulating Factors
(2000-2010): Geographic Regions Ranked by CAGR - Japan,
Europe, US, and Rest of World (includes corresponding
Graph/Chart) II-15
Interferons II-15
Types of Interferons II-16
Interferon-gamma II-16
1a and 1b: Two Key Biochemical Forms of Interferon-ß II-16
PEG-Intron II-16
Types of Interferons II-17
Table 4: World Market for Interferons as Blood Growth
Factors (2000-2010): Geographic Regions Ranked by CAGR -
US, Europe, Japan, and Rest of World (includes
corresponding Graph/Chart) II-17
Interleukins II-17
Types of Interleukins II-18
Table 5: World Market for Interleukins as Blood Growth
Factors (2000-2010): Geographic Regions Ranked by CAGR -
Europe, Japan, US, and Rest of World (includes
corresponding Graph/Chart) II-19
Tissue Growth Factors II-19
Wound Healing Growth Factors II-19
Neurotrophic Growth Factors II-19
Nerve Growth Factor II-19
Vascular Endothelial Growth Factor (VEGF) II-20
Fibroblast Growth Factor (FGF) II-20
Insulin-Like Growth Factor-I (IGF-I) II-20
Insulin-Like Growth Factor-II (IGF-II) II-20
Tissue Growth Factors: Classification Based on Key Source
and Principal Activity II-20
Platelet - Derived Growth Factors in Wound Healing II-21
Thrombopoietin (TPO) II-21
Table 6: World Market for Tissue Growth Factors
(2000-2010): Geographic Regions Ranked by CAGR - US,
Europe, Japan, and Rest of World (includes corresponding
Graph/Chart) II-21
Growth Factors: Their Mode of Action in Tissue Repair II-21
Angiogenesis: Their Role in Wound Healing II-22
Angiogenesis As an Alternative for Cardiac Stents II-22
Applications of Growth Factors II-22
Growth Factors: Application by Compound and Supplier II-23
Growth Factors: Indicated Applications by Site/Course of Action II-23

8. Research and Development Highlights II-24
Maxygen Updates on Factor VII Program II-24
Evaluation of Extended Dosing Schedule of PROCRIT® II-24
PROCRIT® - A Better Option II-24
Nerve Growth Factor Shows Promising Potential Against Diabetes II-24
Cytokines and GM-CSF Found to be Closely Interlinked II-25
GM-CSF Enhances Rate of Survival in Neonates II-25
rG-CSF Well Tolerated in Pneumonia and Severe Sepsis Patients II-25
rG-CSF- Their Influence on Preterm Infants with Sepsis II-26
Serum Macrophage Colony Stimulating Growth Factors Associated
with Thrombocyte and Monocyte II-26
Src Pathway Inactivation in Kit Impairs Blood Cell Growth and
Proliferation II-26
Cole Eye Institute Offers TIMP-3 Mechanism for Preventing
Abnormal Growth of Blood Vessels II-27
Effect of Brain Derived Neurotrophic Factor on Retinal Cells II-27
Orcel™ Exhibits High Growth Factor for Wound Healing and
Cardiovascular Applications II-28
Drug Combination of Macrophage Colony Stimulating Factor
Shows Successful Tolerance Levels II-28
Neotrofin ™ Triggers Neurotrophic Factors II-28
G-CSF Shows Capability for Promoting Neutrophil Production II-28
Insulin-like Growth Factor-1 (IGF) Gene Transfer Accelerates
Wound Healing Process II-29
Hepatocyte Growth Factors - Exhibiting Dual Role II-29
Cortex Pharmaceuticals Ampakines® Promotes Expression of
Neurotrophin II-29
Granulocyte Colony Stimulating Factor Finds Application in
Treating Neonates II-30
Cerebrolysin Promotes Cognition II-30

9. Breakthroughs - A Review II-31
Novel Set of Human Cytokines Unveiled II-31
IGFBP-3 and its Potential to Ward Off Gastric Cancer II-31
Bone Morphogenic Proteins Show Potential for Musculoskeletal
Regeneration II-31
Growth Factors - Their Role in Preventing Heart Stroke II-31
Growth Factor Proteins Shows Promising Results for Treating
Cancer II-31
Neurotrophic Growth Factor Primarily Responsible for Loss of
Vision II-32
Redox-Active Grape Seed Exhibits Favorable Properties for
Dermal Wound Healing II-32
Role of Brain-Derived Neurotrophic Factor on Memory II-32
Nerve Growth Factor Found to Enhance Barium Current and
Insulin Secretion II-32
Lipid Peroxidation May be Associated with Wound Healing II-32
Genentech Inc Unveils Molecule for Stimulating Growth of
Blood Vessels II-33
Connective Tissue Growth Factor Found to Promote Lung Fibroblast II-33
Influence of Insulin-Like Growth Factor on Growth II-33
Regeneron Discovers Angiopoietins Targeted at Blood Vessel
Growth and Repair II-34
Environment and Insulin-Like Growth Factors Stimulate Risk of
Cancer II-34
Cocktail of Neurotrophic Factors Promotes Regeneration of
Torn Nerves II-34
Growth Factors Administration to Stimulate Tissue Repair II-34
Cytokine - Their Role in Combating Hepatitis C Virus II-34
Axokine® Yields Favorable Results Against Obesity II-35
Cell Genesys Unveils GDNF Gene Therapy Targeted Against
Parkinson’s Disease II-35

10. Recent Industry Activity II-36
Pfizer Inks Exclusive Global Licensing Agreement with Scil
Technology II-36
ZGEN Initiates Ph II Trial of Interleukin 21 II-36
FzioMed Bags Health Canada Approval on Oxiplex® II-36
NsGene A/S Implants Encapsulated Cell in Patients II-36
Reliance Life Sciences Takes Over Genemedix II-36
Fraunhofer Institute Introduces First Interferon Beta 1a to
Treat Multiple Sclerosis II-37
Shanghai Wanxing Inks Export Deal for Recombinant Human
Interferon II-37
Hemispherx Enters into Distribution Agreement with Armada II-37
Bayer Launches US Pharmaceuticals Subsidiary II-38
Merck Inks Agreement with Bristol-Myers Squibb and ImClone II-38
CoGenesys Signs Global Licensing Agreement with Vegenics II-38
InterMune Inks New Supply Deal with Boehringer Ingelheim II-38
Boston Life Sciences Adopts New Name of Alseres Pharmaceuticals II-39
Cambrex Divests Bioproducts and Biopharma Subsidiaries II-39
Dragon Divests EPO Business II-39
Caregene and Genzyme Forms Partnership to Develop Cere-120 II-39
Amgen Bags EC Approval on Use of Aranesp(R) in Paediatric
Patients II-40
NsGene to Undertake Phase Ib Clinical Trial of NsG0202 II-40
Roche Receives European approval for NeoRecormon II-40
Bolder Receives Two U.S. Patents for Hematopoietic Factors II-40
Hospira Receives EC Approval on Retacrit II-41
RLS to Initiate Clinical Trials of Erythropoietin II-41
InterMune Drops Phase III trial of Interferon II-41
Chugai to Conduct Additional Trial on Epogin® II-41
Merck KGaA Acquires Serono Labs II-41
CytoPharm Acquires Low-Dose Interferon License from Amarillo
Biosciences II-42
Hospira Signs Agreements with STADA and BIOCEUTICALS for
Erythropoietin II-42
Biocon Bags GEAC Approval to Conduct Clinical Trial of
Granulocyte Colony Stimulating Factor II-42
SII to Conduct Clinical Trials of Rdna Products II-42
Claris to Construct Production Facility for EOP II-42
Mayne and Pliva to End Collaboration on Erythropoietin
Development II-43
GeneMedix Collaborates with CJ Corp. II-43
FzioMed and USC Enter into Licensing Agreement for Oligopeptides II-43
Tercica Receives FDA Approval For Increlex II-43
AnGes MG Enters Into An Agreement with Vical II-44
Corautus and BIA Sign Agreement for VEGF-2 plasmid DNA II-44
Dragon Pharmaceuticals Acquires Oriental Wave II-44
Insmed Enters into Exclusive Agreement with UCSF for IGF-1
Series II-44
Amrad and Ludwig Institute Jointly Focus on the Development
of VEGF-B II-44
GeneMedix Restructures Business II-45
pSivida Limited Collaborates with Ian Wark Research Institute II-45
Amgen Acquires Tularik II-45
BMPI Signs up Luitpold Pharmaceuticals for FDA Approved GEM 21S™ II-45
DPI Receives Approvals for Erythropoietin in Three New Markets II-46
Chugai and Roche Expand Drug Research Synergies II-46
Dragon Pharmaceuticals to Construct New Production Facility II-46
FibroGen Signs Contract with Yamanouchi for Licensing EPO
Small Molecule II-46
Insmed and Tzamal Pharma Sign Agreement for Promoting SomatoKine II-46
Maxygen and Rentschler Enter into a Contract for G-CSF II-46
Maxygen Signs Agreement with Biovitrum for Manufacturing Beta
Interferon II-46
Dragon Pharmaceuticals Signs Agreement with Zhongkai II-47
Dragon Pharmaceuticals Enters into Definitive Agreement with
Oriental Wave II-47
Zymogenetics Bags US FDA Clearance II-47
Ceregene Bags Patent II-47

11. Strategic Corporate Developments in Recent Past II-48
AME Enters into Third Collaboration with Eli Lilly and Company II-48
ViaCell Enters into Licensing Agreement and Collaboration
with Amgen II-48
Ceregene Enters into Licensing Agreement with Genentech II-48
BIOPHARM GmbH Enters into Licensing Contract with DePuy II-48
Maxygen Enters into a Deal with Roche Holding II-48
Dragon Pharmaceuticals Bags Market Approval from Chinese SDA II-49
GeneMedix Signs Agreement with SkyePharma II-49
Neurotech Enters into Licensing Agreement with Amgen II-49
Ceregene Enters into a Licensing Agreement with Washington
University II-49
NeoTherapeutics Receives US Patent for Stimulating
Neuritogenesis II-49
BioSET Bags Global Exclusive License for Novel Growth Factor
Technology II-49
ViaCell Acquires Cerebrotec II-50
Fibrogen Collaborates with Sankyo II-50
Prescient NeuroPharma Collaborates with SRIB II-50
Dragon Pharmaceuticals Signs Agreement with Renapharm AB and
Transworld II-50
Baxter Bags Exclusive Worldwide Rights for Epoetin Omega II-50
Ortec International Bags FDA PMA for OrCel II-50
GeneMedix Bags Chinese SDA Approval II-51
NsGene Collaborates with ARIAD Pharmaceuticals II-51
Regeneron Enters into Agreement with Emisphere Technologies II-51
NsGene A/S Signs Agreement with Biogen Inc II-51
NTB Enters into BioInformatics Outsourcing Agreement with HSC II-52

12. Product Launches in Recent Past II-53
Wockhardt Introduces Wepox Recombinant Erythropoietin Drug II-53
Shanta Biotechnics Unveils Shanferon II-53
SkinMedica Unveils TNS Recovery Complex™ Gel II-53
CellGenix Unveils Cytokines for Cell Applications II-53
Cel-Sci Corporation Develops Multikine II-53
Wockhardt Limited Unveils EPOX™ II-53

13. Focus on Select Global Players II-54
Amgen, Inc. (USA) II-54
BioMimetic Therapeutics, Inc. (USA) II-54
Biopharm GmbH (Germany) II-54
Bolder Biotechnology, Inc. (USA) II-54
Alseres Pharmaceuticals, Inc. (USA) II-55
Ceregene Inc. (USA) II-55
FibroGen Inc. (USA) II-55
FzioMed Inc. (USA) II-55
GeneMedix Plc. (UK) II-56
Insmed Inc. (USA) II-56
Johnson & Johnson (USA) II-56
Janssen-Ortho Inc. (Canada) II-57
Lonza Group (Switzerland) II-57
Maxygen, Inc. (USA) II-57
Merck Serono International S.A. (Switzerland) II-57
NsGene A/S (Denmark) II-58
PeproTech Inc. (USA) II-58
Rentschler Biotechnologie GmbH (Germany) II-58
F. Hoffmann-La Roche Ltd (Switzerland) II-58
Chugai Pharmaceutical Co. Ltd. (Japan) II-59
Genentech Inc. (USA) II-59
Shantha Biotechnics (India) II-59
Scil Proteins GmbH (Germany) II-60
Wockhardt Ltd. (India) II-60

14. Global Market Perspective II-61
Table 7: World Recent Past, Current & Future Analysis for
Growth Factors (Blood and Tissue) by Geographic Region - US,
Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-61

Table 8: World Long-term Projections for Growth Factors (Blood
and Tissue) by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-62

Table 9: World 10-Year Perspective for Growth Factors (Blood
and Tissue) by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-63

Table 10: World Recent Past, Current & Future Analysis for
Blood Growth Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-64

Table 11: World Recent Past, Current & Future Analysis for
Blood Growth Factors by Type - Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) II-65

Table 12: World Long-term Projections for Blood Growth Factors
by Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-66

Table 13: World Long-term Projections for Blood Growth
Factors by Type - Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2011
through 2015 (includes corresponding Graph/Chart) II-67

Table 14: World 10-Year Perspective for Blood Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales
for US, Japan, Europe, and Rest of World Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-68

Table 15: World 10-Year Perspective for Blood Growth Factors
by Type - Percentage Breakdown of Value Sales for
Erythropoietins, Colony Stimulating Factors, Interferons and
Interleukins Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) II-69

Table 16: World Recent Past, Current & Future Analysis for
Erythropoietins by Geographic Region - US, Japan, Europe, and
Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2000 through 2010 (includes
corresponding Graph/Chart) II-70

Table 17: World Long-term Projections for Erythropoietins by
Geographic Region - US, Japan, Europe, and Rest of World
Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-71

Table 18: World 10-Year Perspective for Erythropoietins by
Geographic Region - Percentage Breakdown of Value Sales for
US, Japan, Europe, and Rest of World Markets for 2003, 2008 &
2012 (includes corresponding Graph/Chart) II-72

Table 19: World Recent Past, Current & Future Analysis for
Colony Stimulating Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-73

Table 20: World Long-term Projections for Colony Stimulating
Factors by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-74

Table 21: World 10-Year Perspective for Colony Stimulating
Factors by Geographic Region - Percentage Breakdown of Value
Sales for US, Japan, Europe, and Rest of World Markets for
2003, 2008 & 2012 (includes corresponding Graph/Chart) II-75

Table 22: World Recent Past, Current & Future Analysis for
Interferons as Blood Growth Factors by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-76

Table 23: World Long-term Projections for Interferons as
Blood Growth Factors by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-77

Table 24: World 10-Year Perspective for Interferons as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-78

Table 25: World Recent Past, Current & Future Analysis for
Interleukins as Blood Growth Factors by Geographic Region -
US, Japan, Europe, and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2000
through 2010 (includes corresponding Graph/Chart) II-79

Table 26: World Long-term Projections for Interleukins as
Blood Growth Factors by Geographic Region - US, Japan, Europe,
and Rest of World Markets Independently Analyzed with Annual
Sales in US$ Million for Years 2011 through 2015 (includes
corresponding Graph/Chart) II-80

Table 27: World 10-Year Perspective for Interleukins as Blood
Growth Factors by Geographic Region - Percentage Breakdown of
Value Sales for US, Japan, Europe, and Rest of World Markets
for 2003, 2008 & 2012 (includes corresponding Graph/Chart) II-81

Table 28: World Recent Past, Current & Future Analysis for
Tissue Growth Factors by Geographic Region - US, Japan,
Europe, and Rest of World Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2000 through 2010
(includes corresponding Graph/Chart) II-82

Table 29: World Long-term Projections for Tissue Growth
Factors by Geographic Region - US, Japan, Europe, and Rest of
World Markets Independently Analyzed with Annual Sales in US$
Million for Years 2011 through 2015 (includes corresponding
Graph/Chart) II-83

Table 30: World 10-Year Perspective for Tissue Growth Factors
by Geographic Region - Percentage Breakdown of Value Sales
for US, Japan, Europe, and Rest of World Markets for 2003,
2008 & 2012 (includes corresponding Graph/Chart) II-84


III. MARKET

1. The United States III-1
A.Market Analysis III-1
Current and Future Analysis III-1
EPO Market Scenario III-1
Key Market Driver for EPO III-1
Leading EPO Drugs in the US III-1
Recent Industry Activity III-2
Strategic Corporate Developments in Recent Past III-6
Product Launches in Recent Past III-8
Key Players III-9
B.Market Analytics III-12
Table 31: US Recent Past, Current & Future Analysis for
Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding Graph/Chart) III-12

Table 32: US Long-term Projections for Growth Factors by
Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-13

Table 33: US 10-Year Perspective for Growth Factors by Type
- Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-14

2. Japan III-15
A.Market Analysis III-15
Current and Future Analysis III-15
Erythropoietin Market: Competitive Scenario III-15
Leading EPO Drugs in Japan III-15
Market Scenario for Biotech Products III-15
Biotech Market Backed by Public Assistance III-15
Recent Industry Activity III-16
Chugai Pharmaceutical Co. Ltd. - A Key Player III-16
B.Market Analytics III-17
Table 34: Japanese Recent Past, Current & Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding
Graph/Chart) III-17

Table 35: Japanese Long-term Projections for Growth Factors
by Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-18

Table 36: Japanese 10-Year Perspective for Growth Factors
by Type - Percentage Breakdown of Value Sales for Blood
Growth Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-19

3. Europe III-20
A.Market Analysis III-20
Current and Future Analysis III-20
Erythropoietin Market Scenario in the Recent Past III-20
Leading EPO Drugs in Europe III-20
Recent Industry Activity III-20
Strategic Developments in Recent Past III-22
Product Launch in Recent Past III-24
Key Players III-24
B.Market Analytics III-27
Table 37: European Recent Past, Current & Future Analysis
for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding
Graph/Chart) III-27

Table 38: European Long-term Projections for Growth Factors
by Type - Blood Growth Factors (Erythropoietins, Colony
Stimulating Factors, Interferons and Interleukins) and
Tissue Growth Factors Markets Independently Analyzed with
Annual Sales in US$ Million for Years 2011 through 2015
(includes corresponding Graph/Chart) III-28

Table 39: European 10-Year Perspective for Growth Factors by
Type - Percentage Breakdown of Value Sales for Blood Growth
Factors (Erythropoietins, Colony Stimulating Factors,
Interferons and Interleukins) and Tissue Growth Factors
Markets for 2003, 2008 & 2012 (includes corresponding
Graph/Chart) III-29

4. Rest of World III-30
A.Market Analysis III-30
Current and Future Analysis III-30
An Overview of Indian Market III-30
Erythropoiet III-30 G-CSF III-30
Interferon III-31
Recent Industry Activity III-31
Strategic Developments in Recent Past III-33
Product Launches in Recent Past III-34
Key Players III-35
B.Market Analytics III-36
Table 40: Rest of World Recent Past, Current & Future
Analysis for Growth Factors by Type - Blood Growth Factors
(Erythropoietins, Colony Stimulating Factors, Interferons
and Interleukins) and Tissue Growth Factors Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2000 through 2010 (includes corresponding
Graph/Chart) III-36

Table 41: Rest of World Long-term Projections for Growth
Factors by Type - Blood Growth Factors (Erythropoietins,
Colony Stimulating Factors, Interferons and Interleukins)
and Tissue Growth Factors Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2011 through
2015 (includes corresponding Graph/Chart) III-37

Table 42: Rest of World 10-Year Perspective for Growth
Factors by Type - Percentage Breakdown of Value Sales for
Blood Growth Factors (Erythropoietins, Colony Stimulating
Factors, Interferons and Interleukins) and Tissue Growth
Factors Markets for 2003, 2008 & 2012 (includes
corresponding Graph/Chart) III-38


IV. COMPETITIVE LANDSCAPE


-Alseres Pharmaceuticals, Inc. (USA)
-Amgen, Inc. (USA)
-BioMimetic Therapeutics, Inc. (USA)
-Biopharm GmbH (Germany)
-Bolder Biotechnology, Inc. (USA)
-Ceregene Inc. (USA)
-Chugai Pharmaceutical Co. Ltd. (Japan)
-F. Hoffmann-La Roche Ltd (Switzerland)
-FibroGen Inc. (USA)
-FzioMed Inc. (USA)
-GeneMedix Plc. (UK)
-Genentech Inc. (USA)
-Insmed Inc. (USA)
-Janssen-Ortho Inc. (Canada)
-Johnson & Johnson (USA)
-Lonza Group (Switzerland)
-Maxygen, Inc. (USA)
-Merck Serono International S.A. (Switzerland)
-NsGene A/S (Denmark)
-PeproTech Inc. (USA)
-Rentschler Biotechnologie GmbH (Germany)
-Scil Proteins GmbH (Germany)
-Shantha Biotechnics (India)
-Wockhardt Ltd. (India)